Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC017 SAD, Food Effect, and DDI Study in Healthy Adults
NCT06278389Phase 1Completed
- Sponsor
- Aidea Pharma
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of asuptegravir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Aidea Pharma. Primary endpoints: Adverse Events, Maximum Observed Plasma Concentration and 11 more. Started Jan 2024; status: completed.
02
Drugs
asuptegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06278389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278389.